Developing cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersions.
A new paromomycin micellar nanogel based on poloxamer 407 was developed. In vitro release and ex vivo permeation/retention studies were conducted. In vivo tolerance was assayed by transepidermal water loss. Ex vivo cytotoxicity on RAW and VERO cells and antileishmanial activity on Leishmania promastigotes was tested. The particle size was 9.19 nm (99% loading efficiency) exhibiting Newtonian behavior at 4°C and was pseudoplastic at 25 and 40°C. Drug release followed a Weibull model and the drug remaining in the skin was 31.652 µg/g/cm(2). In vivo tolerance achieved excellent results with negligible cellular toxicity and the best antileishmanial efficiency. The nanogel provided controlled, effective and safe delivery of paromomycin for the treatment of cutaneous leishmaniasis.